Skip to main content
SpringerLink
Log in
Book cover

Le syndrome de Turner pp 71–81Cite as

Syndrome de Turner. Traitement par hormone de croissance

  • Chapter

  • 313 Accesses

Abstrait

Le retard statural, quasi constant dans le syndrome de Turner (95%), est responsable d’une réduction spontanée de la taille adulte d’environ 20 cm par rapport à celle des femmes de même origine ethnique. En France, la taille adulte spontanée moyenne est de 142,5 ± 5,5 cm (1, 2) avec, selon les pays, des extrêmes de taille comprise entre 136 et 161 cm. Dans le syndrome de Turner, le ralentissement statural est progressif et survient en moyenne à partir de l’âge de 18 mois. L’absence de puberté et donc de pic de croissance pubertaire, lié à l’insuffisance ovarienne, majore le déficit statural.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Rochiccioli P, David M, Malpuech G et al. (1994) Study of final height in Turner’s syndrome: ethnic and genetic influences. Acta Paediatr 83: 305–8

    Article  PubMed  CAS  Google Scholar 

  2. Cabrol S, Saab C, Gourmelen M et al. (1996) Turner syndrome: spontaneous growth of stature, weight increase and accelerated bone maturation. Arch Pediatr 3: 313–8

    Article  PubMed  CAS  Google Scholar 

  3. Guyda HJ (1999) Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 84: 4307–16

    Article  PubMed  CAS  Google Scholar 

  4. Rosenfeld RG, Attie KM, Frane J et al. (1998) Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr 132: 319–24

    Article  PubMed  CAS  Google Scholar 

  5. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, et al. (1999) Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 84: 4607–12

    Article  PubMed  CAS  Google Scholar 

  6. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. (2003) Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 88: 1119–25

    Article  PubMed  Google Scholar 

  7. Soriano-Guillen L, Coste J, Ecosse E, et al. (2005) Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab 90: 5197–204.

    Article  PubMed  CAS  Google Scholar 

  8. Bondy CA, Turner Syndrome Study Group (2007) Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 92: 10–25

    Article  PubMed  CAS  Google Scholar 

  9. Stephure DK (2005) Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 90: 3360–6

    Article  PubMed  Google Scholar 

  10. Quigley CA, Crowe BJ, Anglin DG, Chipman JJ (2002) Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 87: 2033–41

    Article  PubMed  CAS  Google Scholar 

  11. Rosenfeld RG (1989) Acceleration of growth in Turner syndrome patients treated with growth hormone: summary of three-year results. J Endocrinol Invest 12(8 Suppl 3): 49–51

    PubMed  CAS  Google Scholar 

  12. Carel JC, Mathivon L, Gendrel C (1998) Near normalization of final height with adapted doses of growth hormone in Turner’s syndrome. J Clin Endocrinol Metab 83: 1462–6

    Article  PubMed  CAS  Google Scholar 

  13. Reiter EO, Blethen SL, Baptista J, Price L (2001) Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner’s syndrome. J Clin Endocrinol Metab 86: 1936–41

    Article  PubMed  CAS  Google Scholar 

  14. Chernausek SD, Attie KM, Cara JF et al. (2000) Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech Inc., Collaborative Study Group. J Clin Endocrinol Metab 85: 2439–45

    Article  PubMed  CAS  Google Scholar 

  15. Massa G, Heinrichs C, Verlinde S et al. (2003) Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final height. J Clin Endocrinol Metab 88: 4168–74

    Article  PubMed  CAS  Google Scholar 

  16. Pasquino AM, Pucarelli I, Segni M et al. (2005) Adult height in sixty girls with Turner syndrome treated with growth hormone matched with an untreated group. J Endocrinol Invest 28: 350–6

    PubMed  CAS  Google Scholar 

  17. Ranke MB, Lindberg A, Ferrández Longás A et al. (2007) Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatr Res 61: 105–10

    Article  PubMed  CAS  Google Scholar 

  18. Davenport ML, Crowe BJ, Travers SH et al. (2007) Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 92: 3406–16

    Article  PubMed  CAS  Google Scholar 

  19. Rosenfield RL, Devine N, Hunold JJ et al. (2005) Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 90: 6424–30

    Article  PubMed  CAS  Google Scholar 

  20. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, et al. (2000) Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab 85: 769–75

    Article  PubMed  CAS  Google Scholar 

  21. Van Pareren YK, De Muinck Keizer-Schrama SM, Stijnen T, et al. (2002) Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J Clin Endocrinol Metab 87: 5442–8

    Article  PubMed  Google Scholar 

  22. Gravholt CH, Naeraa RW, Nyholm B et al. (1998) Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner’s syndrome. The impact of sex hormone replacement. Diabetes Care 21: 1062–70

    Article  PubMed  CAS  Google Scholar 

  23. Bondy CA, Van PL, Bakalov VK, Ho VB. et al. (2006) Growth hormone treatment and aortic dimensions in Turner syndrome. J Clin Endocrinol Metab 91: 1785–8

    Article  PubMed  CAS  Google Scholar 

  24. van den Berg J, Bannink EM, Wielopolski PA et al. (2006) Aortic distensibility and dimensions and the effects of growth hormone treatment in the turner syndrome. Am J Cardiol 97: 1644–9

    Article  PubMed  Google Scholar 

  25. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T et al. (1999) Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Pediatr 135: 470–6

    Article  PubMed  CAS  Google Scholar 

  26. Matura LA, Sachdev V, Bakalov VK, et al. (2007) Growth hormone treatment and left ventricular dimensions in Turner syndrome. J Pediatr 150(6): 587–91

    Article  PubMed  CAS  Google Scholar 

  27. Rubin K (1998) Turner syndrome and osteoporosis: mechanisms and prognosis. Pediatrics 102: 481–5

    PubMed  CAS  Google Scholar 

  28. Sass TC, de Muinck Keizer-Schrama SM, Stijnen T, et al. (2000) A longitudinal study on bone mineral density until adulthood in girls with Turner’s syndrome participating in a growth hormone injection frequency-response trial. Clin Endocrinol (Oxf) 52(5): 531–6

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’endocrinologie et diabétologie pédiatriques, CHU d’Angers Clinique Robert Debré, 4, rue Larrey, 49000, Angers

    R. Coutant

  2. Service d’endocrinologie et diabétologie pédiatriques, Hôpital Robert Debré, 48, boulevard Sérurier, 75019, Paris Cedex 19

    D. Zenaty & J. Léger

Authors
  1. R. Coutant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Zenaty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Léger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag France

About this chapter

Cite this chapter

Coutant, R., Zenaty, D., Léger, J. (2009). Syndrome de Turner. Traitement par hormone de croissance. In: Le syndrome de Turner. Springer, Paris. https://doi.org/10.1007/978-2-287-87855-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-87855-8_7

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-87854-1

  • Online ISBN: 978-2-287-87855-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation